Compare RPID & DHF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RPID | DHF |
|---|---|---|
| Founded | 2006 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 178.6M | 185.7M |
| IPO Year | 2021 | N/A |
| Metric | RPID | DHF |
|---|---|---|
| Price | $3.24 | $2.52 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | 159.8K | ★ 451.1K |
| Earning Date | 02-27-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.65% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $30,523,000.00 | N/A |
| Revenue This Year | $19.36 | N/A |
| Revenue Next Year | $21.48 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 16.63 | N/A |
| 52 Week Low | $0.98 | $2.06 |
| 52 Week High | $4.50 | $2.39 |
| Indicator | RPID | DHF |
|---|---|---|
| Relative Strength Index (RSI) | 47.95 | 54.18 |
| Support Level | $2.70 | $2.47 |
| Resistance Level | $3.45 | $2.54 |
| Average True Range (ATR) | 0.23 | 0.03 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 65.00 | 75.00 |
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.
BNY Mellon High Yield Strategies Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income and its secondary objective is capital appreciation. The fund invests predominantly in fixed-income securities of below-investment-grade credit quality.